Matches in Nanopublications for { <http://bio2rdf.org/drugbank_resource:DB00472_DB01166> ?p ?o ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- drugbank_resource:DB00472_DB01166 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00472_DB01166 label "DDI between Fluoxetine and Cilostazol - Fluoxetine, a moderate CYP2C19 inhibitor, may decrease the metabolism of cilostazol. Monitor for changes in the therapeutic and adverse effects of cilostazol if fluoxetine is initiated, discontinued or dose changed. [drugbank_resource:DB00472_DB01166]" assertion.
- drugbank_resource:DB00472_DB01166 identifier "drugbank_resource:DB00472_DB01166" assertion.
- drugbank_resource:DB00472_DB01166 title "DDI between Fluoxetine and Cilostazol - Fluoxetine, a moderate CYP2C19 inhibitor, may decrease the metabolism of cilostazol. Monitor for changes in the therapeutic and adverse effects of cilostazol if fluoxetine is initiated, discontinued or dose changed." assertion.